The pedunculopontine nucleus in Parkinson's disease

This study demonstrated a significant loss of neurons within the lateral part of the pedunculoponite nucleus pars compacta in individuals with idiopathic Parkinson's disease and in individuals with combined Parkinson's and Alzheimer's disease. We also examined the extent of neuronal loss within the substantia nigra pars compacta, locus ceruleus, dorsal raphe nucleus, and nucleus basalis of Meynert. The number of pedunculopontine nucleus pars compacta neurons in the patients with Parkinson's or Parkinson's and Alzheimer's disease was reduced (average, 40°) in comparison with the number in control subjects or patients with Alzheimer's disease (p < 0.01). This finding correlated significantly with the extent of loss of substantia nigra pars compacta neurons (p < 0.01).

[1]  Y. Agid,et al.  Micro topography of Tyrosine Hydroxylase, Glutamic Acid Decarboxylase, and Choline Acetyltransferase in the Substantia Nigra and Ventral Tegmental Area of Control and Parkinsonian Brains , 1981, Journal of neurochemistry.

[2]  B. Djahanguiri,et al.  The prevention of acute gastric ulcer in the rat by alpha-methyldopa. , 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine.

[3]  H. Kimura,et al.  The central cholinergic system studied by choline acetyltransferase immunohistochemistry in the cat , 1981, The Journal of comparative neurology.

[4]  Y. Agid,et al.  Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia , 1982, Brain Research.

[5]  D. Price,et al.  Loss of pedunculopontine neurons in progressive supranuclear palsy , 1987, Annals of neurology.

[6]  Larry L. Butcher,et al.  Cholinergic systems in the rat brain: III. Projections from the pontomesencephalic tegmentum to the thalamus, tectum, basal ganglia, and basal forebrain , 1986, Brain Research Bulletin.

[7]  K. Jellinger,et al.  The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[8]  D. Price,et al.  Reductions in corticotropin releasing factor‐like immunoreactivity in cerebral cortex in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy , 1987, Neurology.

[9]  E. Perry,et al.  Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[10]  A M Graybiel,et al.  Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Mesulam,et al.  Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1–Ch6) , 1983, Neuroscience.

[12]  J. Meerwaldt,et al.  Factors that influence the occurrence of response variations in Parkinson's disease , 1987, Annals of neurology.

[13]  K. Lloyd,et al.  DISTRIBUTION OF CHOLINE ACETYLTRANSFERASE AND GLUTAMATE DECARBOXYLASE WITHIN THE SUBSTANTIA NIGRA AND IN OTHER BRAIN REGIONS FROM CONTROL AND PARKINSONIAN PATIENTS , 1975, Journal of neurochemistry.

[14]  George C. Cotzias,et al.  Modification of Parkinsonism--chronic treatment with L-dopa. , 1969, The New England journal of medicine.

[15]  D L Price,et al.  Basal forebrain neurons in the dementia of Parkinson disease , 1983, Annals of neurology.

[16]  T. O'donohue,et al.  The distribution of corticotropin releasing factor-like immunoreactive neurons in rat brain , 1982, Peptides.

[17]  E. Garcia-Rill.  The basal ganglia and the locomotor regions , 1986, Brain Research Reviews.

[18]  F Lhermitte,et al.  Does long‐term aggravation of Parkinson's disease result from nondopaminergic lesions? , 1987, Neurology.

[19]  H. Fibiger,et al.  Substance P in the ascending cholinergic reticular system , 1983, Nature.

[20]  K. Jellinger,et al.  Overview of morphological changes in Parkinson's disease. , 1987, Advances in neurology.

[21]  M. Mesulam,et al.  Atlas of cholinergic neurons in the forebrain and upper brainstem of the macaque based on monoclonal choline acetyltransferase immunohistochemistry and acetylcholinesterase histochemistry , 1984, Neuroscience.

[22]  P. Mcgeer,et al.  ENZYMES ASSOCIATED WITH THE METABOLISM OF CATECHOLAMINES, ACETYLCHOLINE AND GABA IN HUMAN CONTROLS AND PATIENTS WITH PARKINSON'S DISEASE AND HUNTINGTON'S CHOREA , 1976, Journal of neurochemistry.

[23]  D. Price,et al.  Cellular pathology in Alzheimer's and Parkinson's diseases , 1986, Trends in Neurosciences.

[24]  D. Price,et al.  The neuropathology of aminergic nuclei in Alzheimer's disease , 1988, Progress in clinical and biological research.

[25]  H. Kimura,et al.  The cholinergic system of the human hindbrain studied by choline acetyltransferase immunohistochemistry and acetylcholinesterase histochemistry , 1986, Brain Research.

[26]  Robert W. McCarley,et al.  Site-specific enhancement and suppression of desynchronized sleep signs following cholinergic stimulation of three brainstem regions , 1984, Brain Research.

[27]  D. Price,et al.  Reductions in acetylcholine and nicotine binding in several degenerative diseases. , 1988, Archives of neurology.

[28]  H. Fibiger,et al.  Distribution of central cholinergic neurons in the baboon (papio papio). I. General morphology , 1985, The Journal of comparative neurology.

[29]  A. Beaudet,et al.  Retrograde labeling of neurons in the brain stem following injections of [3H]choline into the rat spinal cord , 1986, Neuroscience.

[30]  Y. Agid,et al.  Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains , 1983, Brain Research.

[31]  A M Graybiel,et al.  The afferent and efferent connections of the feline nucleus tegmenti pedunculopontinus, pars compacta , 1983, The Journal of comparative neurology.

[32]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[33]  C. Markham,et al.  Sleep in patients with Parkinson's disease and normal subiects prior to and following levodopa administration , 1971, Clinical pharmacology and therapeutics.

[34]  A. Levey,et al.  The origins of cholinergic and other subcortical afferents to the thalamus in the rat , 1987, The Journal of comparative neurology.